PD-L1 expression

Immunotherapy-related pneumonitis ≥grade 1 was documented in 15.7% patients. In real-world practice, durvalumab improves OS and PFS in PD-L1-positive unresectable stage III NSCLC and its omission appears particularly unfavourable.

Active surveillance represents a promising alternative to immediate esophagectomy in selected patients with cCR after neoadjuvant therapy. However, further studies with longer follow-up and standardized surveillance protocols are still needed to safely implement this strategy outside trial settings.

P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

Herein, we engineered a multifunctional ultrasound (US)-responsive nanomodulator (SPNacs) through the co-assembly of a semiconducting polymer sonosensitizer (PF8DPP) and curcumin (Cur) with a reactive oxygen species (ROS)-cleavable polymer shell containing both bone and neutrophil dual-targeting ligands (alendronate and sialic acid)...Consequently, a synergistic effect was achieved to simultaneously suppressed tumor progression and fostered bone tissue regeneration. Collectively, this study presents a promising therapeutic strategy that addresses both tumor eradication and skeletal repair within metastatic bone lesions.

We established a robust pooled PBMC-organoid co-culture platform that enables functional assessment of tumor-immune dynamics in PMGCs. This system serves as a functional ex vivo tool for evaluating immunotherapy responses and for examining the expression patterns of alternative immune checkpoint ligands associated with differential PD-1 blockade response. These findings support the utility of this ex vivo PMGC co-culture system for evaluating heterogeneous responses to PD-1 blockade and associated baseline differences in alternative immune checkpoint ligand expression among PD-L1-high organoids.

RIG-I activation via 3p-RNA therapy shows promise as an immunotherapeutic strategy for hepatocellular carcinoma (HCC). Future investigations need to focus on tumor-intrinsic factors to understand heterogeneity between tumors and to overcome resistance mechanisms.

PD-L1 testing should remain assay-, tissue-, and indication-specific, supported by regulatory approval and clinical outcome data. Future integration of digital tools and multimodal biomarkers may improve standardization and predictive accuracy.

These findings highlight multiple potential immunologic correlates of pembrolizumab with CRT in high-risk HNSCC, supporting further evaluation and validation in larger, adequately powered trials.

In addition, therapeutic vaccines continue to be studied as a promising approach to preventing relapses in high-risk patients when combined with other immunotherapy agents. This represents a major advance in the treatment of the most aggressive subtypes of breast cancer, positioning immunotherapy as one of the most promising treatments.

These findings suggest that iSBRT + anti-PD-L1 may convert immune-cold ER+HER2- BC into more inflamed tumors and improve response, particularly in PD-L1-negative disease. ClinicalTrials.gov registration: NCT03875573 .

Sequential systemic chemotherapy including durvalumab is suggested as a useful future treatment option and may contribute to conversion surgery for unresectable ampulla of Vater carcinoma.

The results may reflect the utility of the expert led standardized protocol used to train pathologists for scoring PD-L1 staining in NSCLC specimens. The digital image-led training approach has the additional advantage of providing a computer-assisted scoring system and allows for remote training of pathologists worldwide.